Shanghai Rendu Biotechnology Co. Ltd. A - Asset Resilience Ratio

Latest as of March 2026: 70.50%

Shanghai Rendu Biotechnology Co. Ltd. A (688193) has an Asset Resilience Ratio of 70.50% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥693.75 Million

≈ $101.52 Million USD Cash + Short-term Investments

Total Assets

CN¥984.02 Million

≈ $143.99 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Shanghai Rendu Biotechnology Co. Ltd. A's Asset Resilience Ratio has changed over time. See 688193 financial flexibility score to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Rendu Biotechnology Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688193 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥693.75 Million	70.5%
Total Liquid Assets	CN¥693.75 Million	70.50%

Asset Resilience Insights

Very High Liquidity: Shanghai Rendu Biotechnology Co. Ltd. A maintains exceptional liquid asset reserves at 70.50% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Shanghai Rendu Biotechnology Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Shanghai Rendu Biotechnology Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
LONZA GROUP UNSP.ADR 1/10 F:LO3A	Diagnostics & Research	3.04%
Dr. Lal Path Labs Ltd. NSE:LALPATHLAB	Diagnostics & Research	13.43%
BGI Genomics Co Ltd SHE:300676	Diagnostics & Research	3.62%
Fleury S.A. SA:FLRY3	Diagnostics & Research	16.06%
Centro de Imagem Diagnósticos S.A SA:AALR3	Diagnostics & Research	4.77%
Inoviq Ltd AU:IIQ	Diagnostics & Research	56.29%
RHYTHM Biosciences Ltd AU:RHY	Diagnostics & Research	2.74%
Immunovia publ AB ST:IMMNOV	Diagnostics & Research	83.99%

Annual Asset Resilience Ratio for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Rendu Biotechnology Co. Ltd. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	70.04%	CN¥693.47 Million ≈ $101.48 Million	CN¥990.17 Million ≈ $144.89 Million	+18.65pp
2024-12-31	51.39%	CN¥510.96 Million ≈ $74.77 Million	CN¥994.36 Million ≈ $145.51 Million	+46.63pp
2023-12-31	4.76%	CN¥50.21 Million ≈ $7.35 Million	CN¥1.05 Billion ≈ $154.34 Million	-44.01pp
2022-12-31	48.77%	CN¥530.98 Million ≈ $77.70 Million	CN¥1.09 Billion ≈ $159.31 Million	+31.60pp
2019-12-31	17.17%	CN¥32.12 Million ≈ $4.70 Million	CN¥187.07 Million ≈ $27.37 Million	--

pp = percentage points

About Shanghai Rendu Biotechnology Co. Ltd. A

SHG:688193 China Diagnostics & Research

Market Cap

$251.48 Million

CN¥1.72 Billion CNY

Market Cap Rank

#15528 Global

#4482 in China

Share Price

CN¥42.89

Change (1 day)

-3.03%

52-Week Range

CN¥42.89 - CN¥61.67

All Time High

CN¥63.91